Results 131 to 140 of about 12,047 (282)

Treatment of Aspergillosis. [PDF]

open access: yes, 2018
Infections caused by Aspergillus spp. remain associated with high morbidity and mortality. While mold-active antifungal prophylaxis has led to a decrease of occurrence of invasive aspergillosis (IA) in those patients most at risk for infection ...
Hoenigl, Martin, Jenks, Jeffrey D
core   +1 more source

Effect of statin use on outcomes of adults with candidemia [PDF]

open access: yes, 2016
Background: Statins have immunomodulatory properties and hinder Candida growth. However, it is unknown whether they may improve prognosis in patients with candidemia.
Ayats, Josefina   +11 more
core   +1 more source

Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis

open access: yesFrontiers in Pharmacology
BackgroundThis meta-analysis aims to evaluate the effectiveness and safety of combining echinocandins with standard of care (SOC) antifungal drugs for treating invasive aspergillosis infection (IAI).MethodWe searched PubMed, Embase, and Cochrane Library ...
Yazed Saleh Alsowaida   +6 more
doaj   +1 more source

[Anidulafungin].

open access: yesRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2008
Anidulafungin is a new echinocandin antifungal agent recently approved in Spain by the Spanish Drug Agency. As other echinocandins, it inhibits a selective target, 1,3- beta-D-glucan synthesis, a major structural component of the fungal cell wall which is not present in mammalian cells, this avoiding toxicity problems.
M, Gobernado, E, Cantón
openaire   +1 more source

Anidulafungin for the treatment of invasive candidiasis [PDF]

open access: bronze, 2011
Astrid Mayr   +2 more
openalex   +1 more source

Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults

open access: yesAntimicrobial Agents and Chemotherapy, 2018
In 2025, approximately one out of five adults will be obese. Physiological changes associated with obesity have been shown to influence the pharmacokinetics of drugs.
R. Wasmann   +6 more
semanticscholar   +1 more source

Gene Expression of Pneumocystis murina after Treatment with Anidulafungin Results in Strong Signals for Sexual Reproduction, Cell Wall Integrity, and Cell Cycle Arrest, Indicating a Requirement for Ascus Formation for Proliferation

open access: yesAntimicrobial Agents and Chemotherapy, 2018
The echinocandins are a class of antifungal agents that target β-1,3-d-glucan (BG) biosynthesis. In the ascigerous Pneumocystis species, treatment with these drugs depletes the ascus life cycle stage, which contains BG, but large numbers of forms which ...
M. Cushion   +6 more
semanticscholar   +1 more source

Anidulafungin increases the antibacterial activity of tigecycline in polymicrobial Candida albicans/Staphylococcus aureus biofilms on intraperitoneally implanted foreign bodies

open access: yesJournal of Antimicrobial Chemotherapy, 2018
Objectives We aimed to establish a novel murine intra-abdominal foreign body infection model to study the activity of anidulafungin and tigecycline against dual species Candida albicans/Staphylococcus aureus biofilms.
Ona Rogiers   +7 more
semanticscholar   +1 more source

Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients [PDF]

open access: bronze, 2018
René Welte   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy